Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485591 | 1.00 | TAAR1 (0.56) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL485589 | 1.00 | TAAR1 (0.56) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL20289497 | 0.79 | TAAR1 (0.61) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL8862845 | 0.79 | TAAR1 (0.61) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL6630553 | 0.79 | TAAR1 (0.61) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL2848530 | 0.78 | TAAR1 (0.51) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL11941179 | 0.78 | TAAR1 (0.51) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL1314696 | 0.78 | TAAR1 (0.51) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL2848529 | 0.78 | TAAR1 (0.51) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL19367694 | 0.75 | MAPT (0.67) | TAAR1MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161277-B1 | Asymmetric synthesis of peptides | UNIV READING (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| US-7612226-B2 | Amino acid derivatives | PFIZER INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1879567-A1 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060247291-A1 | Amino acid derivatives | PFIZER, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006092692-A1 | USE OF COMBINATIONS OF PDE7 INHIBITORS AND ALPHA-2-DELTY LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885MAPT 4877/4885NPC1 3210/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TAAR1 4546/4885MAPT 2065/4885NPC1 37/4885 |
| US-20060247291-A1 | Amino acid derivatives | OPRL1, BCAT2, BCAT1 | TAAR1 207/4885MAPT 2377/4885NPC1 3847/4885 |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885MAPT 4877/4885NPC1 3210/4885 |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885MAPT 4877/4885NPC1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.